Lcatibant Viatris

Icatibant, the active ingredient in Lcatibant Viatris, is a bradykinin B2 receptor antagonist presented as a subcutaneous injection for subcutaneous use. It treats acute attacks of hereditary angioedema in patients with confirmed HAE. GNH USA supplies Lcatibant Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Icatibant acts on the bradykinin pathway to relieve swelling in hereditary angioedema. - Hereditary angioedema (type I): provides rapid reduction of subcutaneous and facial swelling during acute attacks. - Hereditary angioedema (type II): alleviates airway and gastrointestinal edema in emergency episodes. - Hereditary angioedema (C1‑inhibitor deficiency): restores normal vascular permeability during sudden attacks.

Icatibant may cause a range of adverse reactions.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Redness or erythema: localized skin redness. - Swelling at injection site: transient increase in local tissue volume. - Headache: occasional mild to moderate headache. - Nausea: occasional feeling of queasiness. - Dizziness: transient light‑headedness.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Severe hypotension: marked drop in blood pressure. - Angioedema unrelated to HAE: unexpected swelling in other body parts. - Urticaria: widespread hives. - Severe injection‑site necrosis: tissue damage at the site. - Thrombocytopenia: low platelet count observed in rare cases.

Before initiating therapy, clinicians should evaluate patient history and monitor for potential risks. - Confirm diagnosis: ensure the patient has hereditary angioedema before use. - Hypersensitivity: assess for known allergy to icatibant or formulation components. - Pregnancy and lactation: prescribe only if the potential benefit justifies the risk. - Renal or hepatic impairment: monitor clinical response and adjust observation as needed. - Concomitant ACE‑inhibitors: consider increased bradykinin levels that may affect efficacy. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant has limited drug‑drug interactions, but certain agents may modify its effectiveness or safety profile.

Major Interactions (Avoid): - ACE inhibitors: may increase bradykinin levels, potentially reducing icatibant efficacy. - Estrogen‑containing contraceptives: can exacerbate hereditary angioedema attacks.

Moderate Interactions (Monitor Closely): - Other bradykinin B2 antagonists: additive pharmacologic effects may increase risk of hypotension. - C1‑inhibitor concentrate: concurrent use may complicate clinical assessment of response. - NSAIDs: may heighten risk of local injection‑site reactions. - Diuretics: monitor blood pressure due to possible additive hypotensive effect.